The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
in the last 2 years (and before) the ceo and cfo have had packages worth well over 50% of the total revenue. what a joke. i mean how is berringer commanding a basic of nearly £500k and why the **** are they getting bonuses on top!?
2021 packages versus revenue - ceo £678,000, cfo £345,000 so £1.23m they take from £2m revenue so nearly 62%.
2022 - ceo £574,000, cfo £357,000, £931,000 of £1.5m revenue £1.5m so just over 62%.
what a joke.
Sound, fair enough but this isn’t one that came out of the blue so selling over weeks looks fishy. As I say a raise inevitable. The selling could have been shorts but I doubt it. Some IIs have also been reducing (not rathbones as that’s nominees).
Anyway, short term pain and might be long term gain. Need a new CEO/CFO.
They certainly need to look closely at the identity of the seller over the last couple of weeks.
I’m sorry the above shows a complete lack of understanding. Whoever sold looked at their accounts and knew a raise in H1 inevitable so they rightly reduced their stake. That’s why I said it’s crazy to buy even with stupid LinkedIn posts as a raise en route.
CEO has no credibility. The raise will be oversubscribed given the price but there has been someone dumping for weeks. I do feel sorry for any newbies buying as a result of the incessant ramping here. Anyway, may well come good but always do your own research and read past RNSs. A lot of regurgitation today.
As I said I’m not gloating but pointing out it’s not healthy when a BB becomes too rampy and an echo chamber. As you know I’ve been invested for years and when I post a view which is balanced other holders should listen and not have the resident ramper throwing a hissy fit and trying to discredit.
I hope it comes good and maybe the BoD will buy lots of shares and not just a token number.
This is what you gave me stick for writing a few weeks ago -
I’m sure most know money is needed here before end of H1 (for auditors to sign off on accounts without ‘going concern’). I hold here and will buy more once funding clear. If they raise at a premium I’ll have to pay more but given the dire conditions and how hard raises are it might not happen. Potential here clearly massive but the market unforgiving and it’s been said potential massive for years.
Today MIRI wrote -
Shareholders should be aware that if the Fundraising does not complete by 30 June 2024, the Company's annual report and accounts will not be signed off by the Company's auditors on a going concern basis.
Anyway, I’m not happy with the discount and doubling of shares but it was likely and some incessant posters need to take stock and realise others with a different view are being honest and certainly not short.
this was from the 3p raise 12 months ago -
1. the announcements made by amazon and nbcu that they were, or intended, to enter the in-content advertising market;
2. conversations that the company is having with a number of tier 1 content supply businesses in the us. the company is working with five of the top ten largest content supply companies in the us and in dialogue with another four;
anyway, a lot of the same material as 12 months ago and 12 months before that albeit they are now looking to break even next year. all the linkedin posts etc have been posted for years. i’ve been invested here for many years and have seen it all. i moaned years ago about stephan’s package being 50% of the year’s revenue and he has **** all shares. says it all. no skin in the game.
i did call this and recently got stung on avacta which 2phevs thought funny.
anyway, they’ll be over subscribed i suspect given the shocking price and now doubling number of shares. ceo a joke.
You must type like an experienced secretary as they're long winded to say the least. Bizarre you spend a lot of time posting on a company you just trade in as you do with sometimes 20 others. Each to their own
Wynd you said you have 10 to 20 stocks you trade to make a modest percentage on which makes sense. Given this is one of 10 to 20 how come you have posted 175 times on here in the last 30 days? Really prolific, is this your job now to save shareholders from themselves? Surprised you can find the time with up to 20 stocks to trade on
They're holding for nominees so retail and wouldn't be listed on avacta's website
Zak and others are saying the recent fall to 43p if where it needs to close above. Anyway, we'll see but yeah 2 weekly RNS soon and who knows where else other news could come from.
I agree BV. To be honest if they have not sorted funding out by the end of this year through deals or sale of DX it will be poor. 2 weekly should highlight even more efficacy data, more 3 weekly data to come as 4 patients with high fap continue to take drug and were showing reductions (albeit small but expected to reduce further) and they are working on more potent toxins which will be revealed in H2 which is not dissimilar to a for sale sign. Defo makes sense to go for the ACDs rather than 3996 and other older molecules.
It's never easy to oust a CEO and founder of a business and one who has likely run the co like a private business for too long. Chris seems to have a different view on how to move forwards whereas AS wanted to IND 3996 whereas CC seems to want to look at the more toxic newer drugs which to me makes sense. Most large pharma are going for ADCs so if we're able to improve upon them so the next generation then this will surely accelerate interest rather than applying our amazing tech to older albeit better known molecules. Now the pathfinder, 6000, has shown the platform works it's time to apply to the newer therapies and make them even better. No doubt an awful few months for holders but surely a low point and upwards fromhere.
Worth remembering we still had several patients taking drug in the 3 week study and data will be presented so surely the results will improve and even more PFS and patients lives extended without the awful side effects. News on 2 weekly soon too and hopefully some BOD appointments too
Yep and who knows they could get a strategic investor in. I hope retail have a chance to take part. I do think revenues will really pick up in Q4 so if they raise imminently it won't be for too much, it'll depend on what's booked for the auditor to have visibility on revenues. Onwards and upwards
Yep, fair enough LOTM will keep it civil. You sound genuine so all good and not a pump and dump merchant.
Potential here huge but I believe one more raise needed and if it's to retail I'll take part and if strategic investors I'll have to buy more higher. All good either way
2Phevs you sad little creep I still remember you pumping here incessantly every day and then to dump most of your shares as one of our collaborators were working with a rival. Funny as.
Yeah Avacta a shame but the science sound but sadly got their pants pulled down raising in this climate but all okay as haven't sold any and 2 year cash runway so will come good. That;s why I'm nervous here, cash will be needed and revenues massively weighted to end of the year. You're doing your pump so when are you dumping this time?
Hi, this is tickboo, I hold here and expect this to come very good indeed but I've been consistent in saying I expect a raise H1 so waiting to buy more. Amazon has been working on their version for a good while. Liking LinkedIn posts doesn't mean they are working together it's just what you do! I like competitors posts, it's a small world!
CC is based here BTW.
More board appointments will follow and I suspect TG will be toast. Can’t change both so give CC time to get her CFO spot on. Onwards and upwards.
I think the clinicians, oncologists and scientists understand the progress a lot more than the market. Targeting so good as can be seen in data they are able to go for 2 weekly dosing and as a first line treatment. There is no way oncologists would be recommending that if the data wasn't directing them there. They have a duty of care to their patients.